You just read:

Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis

News provided by

Sun Pharma

Mar 21, 2018, 09:04 ET